دورية أكاديمية
أعرض في EDS

Antitumoral effects of γCdcPLI, a PLA 2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.

التفاصيل البيبلوغرافية
العنوان: Antitumoral effects of γCdcPLI, a PLA 2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.
المؤلفون: Gimenes SNC; Federal University of Uberlandia, Uberlandia, MG, Brazil., Lopes DS; Federal University of Uberlandia, Uberlandia, MG, Brazil., Alves PT; Federal University of Uberlandia, Uberlandia, MG, Brazil., Azevedo FVPV; Federal University of Uberlandia, Uberlandia, MG, Brazil., Vecchi L; Federal University of Uberlandia, Uberlandia, MG, Brazil., Goulart LR; Federal University of Uberlandia, Uberlandia, MG, Brazil., Rodrigues TCS; Federal University of Uberlandia, Uberlandia, MG, Brazil., Santos ALQ; Federal University of Uberlandia, Uberlandia, MG, Brazil., Brites VLC; Federal University of Uberlandia, Uberlandia, MG, Brazil., Teixeira TL; Federal University of Uberlandia, Uberlandia, MG, Brazil., da Silva CV; Federal University of Uberlandia, Uberlandia, MG, Brazil., Dias MH; Butantan Institute, São Paulo, Brazil., Teixeira SC; Federal University of Uberlandia, Uberlandia, MG, Brazil., Rodrigues RS; Federal University of Uberlandia, Uberlandia, MG, Brazil., Yoneyama KAG; Federal University of Uberlandia, Uberlandia, MG, Brazil., Oliveira RA; Federal University of Uberlandia, Uberlandia, MG, Brazil., Rodrigues VM; Federal University of Uberlandia, Uberlandia, MG, Brazil. veridiana@ufu.br.
المصدر: Scientific reports [Sci Rep] 2017 Aug 01; Vol. 7 (1), pp. 7077. Date of Electronic Publication: 2017 Aug 01.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Breast Neoplasms*, Antineoplastic Agents/*pharmacology , Lipoproteins/*pharmacology , Oncogene Protein v-akt/*metabolism , Phosphatidylinositol 3-Kinase/*metabolism , Phospholipase A2 Inhibitors/*pharmacology, Antineoplastic Agents/isolation & purification ; Cell Adhesion/drug effects ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Survival/drug effects ; Crotalid Venoms/chemistry ; Endothelial Cells/drug effects ; Humans ; Lipoproteins/isolation & purification ; Models, Biological ; Neovascularization, Pathologic ; Phospholipase A2 Inhibitors/isolation & purification
مستخلص: Phospholipases A 2 (PLA 2 s) overexpression is closely associated with the malignant potential of breast cancers. Here, we showed for the first the antitumoral effects of γCdcPLI, a PLA 2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 cell. Firstly, γCdcPLI was more cytotoxic to MDA-MB-231 breast cancer cells than other cell lines (MCF-7, HeLa, PC3 and A549) and did not affect the viability of non-tumorigenic breast cell (MCF 10A). In addition, γCdcPLI induced modulation of important mediators of apoptosis pathways such as p53, MAPK-ERK, BIRC5 and MDM2. γCdcPLI decreased MDA-MB-231 adhesion, migration and invasion. Interestingly, the γCdcPLI also inhibited the adhesion and migration of endothelial cells and blocked angiogenesis by inhibiting tube formation by HUVECs in vitro and sprouting elongation on aortic ring assay ex vivo. Furthermore, γCdcPLI reduced the production of vascular endothelial growth factor (VEGF). γCdcPLI was also able to decrease PGE2 levels in MDA-MB-231 and inhibited gene and protein expression of the PI3K/Akt pathway. In conclusion, γCdcPLI showed in vitro antitumoral, antimestatatic and anti-angiogenic potential effects and could be an attractive approach for futures studies in cancer therapy.
References: PLoS One. 2010 Apr 12;5(4):e10124. (PMID: 20405031)
J Biol Chem. 2001 Jan 12;276(2):1564-9. (PMID: 11036077)
Toxicol Appl Pharmacol. 2014 Oct 1;280(1):10-20. (PMID: 25094029)
Neuro Oncol. 2010 Oct;12(10):1014-23. (PMID: 20639215)
Nature. 1992 Jul 2;358(6381):80-3. (PMID: 1614537)
Am J Pathol. 2008 Mar;172(3):809-17. (PMID: 18276787)
FASEB J. 2017 Mar;31(3):1107-1119. (PMID: 27974593)
Nat Protoc. 2011 Dec 22;7(1):89-104. (PMID: 22193302)
Interv Med Appl Sci. 2014 Dec;6(4):139-46. (PMID: 25598986)
Biochimie. 2014 Dec;107 Pt A:114-23. (PMID: 25286228)
Breast Cancer Res. 2009;11(1):R1. (PMID: 19123925)
Biochem Biophys Res Commun. 2014 Feb 28;445(1):230-5. (PMID: 24508801)
J Clin Invest. 1997 Feb 1;99(3):373-6. (PMID: 9022067)
Breast Cancer Res Treat. 2013 Aug;140(3):587-601. (PMID: 23912956)
Dig Dis Sci. 1998 Oct;43(10):2261-6. (PMID: 9790463)
Ann Intern Med. 2007 Mar 6;146(5):376-89. (PMID: 17339623)
Methods Mol Biol. 2016;1430:205-19. (PMID: 27172956)
Cancer Res. 1997 Mar 1;57(5):963-9. (PMID: 9041202)
Cytokine Growth Factor Rev. 2005 Feb;16(1):77-89. (PMID: 15733833)
Methods Cell Biol. 2011;103:55-98. (PMID: 21722800)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Breast Cancer Res Treat. 2008 Sep;111(1):27-44. (PMID: 17922188)
Biochem J. 2011 Dec 1;440(2):251-62. (PMID: 21834793)
BMC Cancer. 2013 Nov 14;13:545. (PMID: 24229379)
Br J Cancer. 1994 Jun;69(6):1166-70. (PMID: 8198986)
Breast Cancer Res Treat. 2010 Nov;124(1):63-77. (PMID: 20052536)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Bioorg Med Chem. 2016 Jul 1;24(13):3029-34. (PMID: 27234891)
Int J Cancer. 2015 Nov 15;137(10 ):2424-31. (PMID: 25974157)
J Biol Chem. 2013 Feb 1;288(5):3289-304. (PMID: 23235151)
Breast Cancer Res Treat. 2008 Sep;111(2):209-18. (PMID: 17932742)
Nat Rev Cancer. 2010 Mar;10(3):181-93. (PMID: 20168319)
Exp Cell Res. 2003 Feb 15;283(2):247-55. (PMID: 12581744)
Phytother Res. 2015 Jul;29(7):969-77. (PMID: 25907962)
Chem Biol Interact. 2014 Mar 5;210:51-63. (PMID: 24365254)
Toxicol Appl Pharmacol. 2013 Oct 1;272(1):37-48. (PMID: 23747687)
BMC Complement Altern Med. 2016 Feb 27;16:86. (PMID: 26922065)
Cancer. 1993 May 15;71(10 ):3058-64. (PMID: 8490834)
Oncogene. 2004 Oct 21;23 (49):8146-53. (PMID: 15361831)
J Biol Chem. 2001 Mar 9;276(10):7320-6. (PMID: 11058599)
Toxicon. 2014 Aug;86:16-27. (PMID: 24814013)
Cell. 2001 Feb 23;104(4):487-501. (PMID: 11239407)
Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. (PMID: 23143756)
Stem Cells. 2016 Sep;34(9):2290-305. (PMID: 27301070)
Oncogene. 2007 May 14;26(22):3279-90. (PMID: 17496922)
Cell. 1989 Jun 30;57(7):1083-93. (PMID: 2525423)
Breast Cancer Res. 2008;10 Suppl 1:S2. (PMID: 19091006)
J Biol Chem. 2001 May 25;276(21):18075-81. (PMID: 11278548)
Semin Cancer Biol. 2015 Dec;35:180-90. (PMID: 26192967)
J Cancer Res Clin Oncol. 2011 Nov;137(11):1587-94. (PMID: 21904903)
Cell. 2002 Sep 20;110(6):673-87. (PMID: 12297042)
Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78. (PMID: 15863032)
Toxicon. 2014 Apr;81:58-66. (PMID: 24513130)
Cancer Res. 1998 Sep 15;58(18):4023-37. (PMID: 9751603)
J Biol Chem. 1992 Jun 5;267(16):10931-4. (PMID: 1375931)
Pharmacol Res. 2015 Mar;93:1-10. (PMID: 25533812)
Int J Biochem Cell Biol. 2013 May;45(5):1012-5. (PMID: 23428797)
Head Neck. 2016 Apr;38 Suppl 1:E360-71. (PMID: 25580586)
J Clin Invest. 2007 Nov;117(11):3155-63. (PMID: 17975657)
Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86. (PMID: 15863033)
Cell. 1996 Dec 27;87(7):1153-5. (PMID: 8980221)
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8. (PMID: 12516034)
Science. 1989 Apr 14;244(4901):217-21. (PMID: 2649981)
Oncogene. 2007 Feb 26;26(9):1338-45. (PMID: 17322919)
Mol Cancer. 2013 Sep 27;12(1):111. (PMID: 24070020)
Toxicol Appl Pharmacol. 2014 Sep 15;279(3):311-21. (PMID: 25026504)
Cardiovasc Res. 1996 Oct;32(4):687-98. (PMID: 8915187)
Cancer Res. 2002 Jan 1;62(1):63-6. (PMID: 11782360)
Toxicol Pathol. 2007 Jun;35(4):495-516. (PMID: 17562483)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786)
Front Oncol. 2015 Apr 27;5:89. (PMID: 25964882)
Science. 1990 Aug 24;249(4971):912-5. (PMID: 2144057)
Prostate. 2015 Sep;75(13):1394-402. (PMID: 26073992)
J Cell Biol. 2002 Jul 22;158(2):235-46. (PMID: 12135983)
Bioorg Chem. 2016 Jun;66:124-31. (PMID: 27149364)
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26. (PMID: 15459662)
Int J Dev Biol. 2011;55(4-5):447-53. (PMID: 21858770)
FASEB J. 2015 Sep;29(9):4036-45. (PMID: 26085132)
Biochem Pharmacol. 2007 Oct 1;74(7):949-59. (PMID: 17531957)
Int J Cancer. 2005 Nov 10;117(3):409-17. (PMID: 15906362)
Mutat Res. 1999 Dec 17;431(2):199-209. (PMID: 10635987)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
Breast Dis. 2010;32(1-2):35-48. (PMID: 21778573)
Genome Biol. 2001;2(3):REVIEWS3005. (PMID: 11276432)
Nat Med. 1997 Aug;3(8):917-21. (PMID: 9256286)
Vasc Health Risk Manag. 2006;2(3):213-9. (PMID: 17326328)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Crotalid Venoms)
0 (Lipoproteins)
0 (Phospholipase A2 Inhibitors)
EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
EC 2.7.11.1 (Oncogene Protein v-akt)
تواريخ الأحداث: Date Created: 20170803 Date Completed: 20190212 Latest Revision: 20190215
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5539153
DOI: 10.1038/s41598-017-07082-2
PMID: 28765552
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-017-07082-2